GlassScriptPhysician profile
Aniko Toth-Bagi
NPI 1851362123
$5,673.22
in general payments reported to CMS, 2019-2025
25 companies · $739 in 2025
The $739 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $522 · 2021: $1,250 · 2022: $811 · 2023: $805 · 2024: $804 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,047.80 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $795.51 | 2019-2024 | Xarelto |
| Abbvie INC. | $699.64 | 2021-2025 | Dalvance |
| Novartis Pharmaceuticals Corporation | $676.24 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $367.88 | 2019-2025 | Zerbaxa, Dificid, Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.26 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $274.79 | 2019-2024 | Lokelma, Farxiga |
| Allergan, INC. | $250.17 | 2019-2020 | |
| Boston Scientific Corporation | $194.00 | 2019-2024 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.29 | 2020-2025 | Xifaxan |
| Gilead Sciences, INC. | $142.64 | 2021-2024 | Veklury |
| Otsuka America Pharmaceutical, INC. | $122.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $119.59 | 2020-2024 | Eliquis |
| Alexion Pharmaceuticals, INC. | $76.47 | 2021-2024 | Ultomiris |
| Melinta Therapeutics, LLC | $74.50 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $66.36 | 2022-2023 | Nuzyra |
| Sk Life Science, INC. | $60.26 | 2025 | |
| Novo Nordisk INC | $36.23 | 2023 | Ozempic, Rybelsus |
| Cvrx, INC. | $29.72 | 2022 | |
| Sunovion Pharmaceuticals INC. | $28.37 | 2019 | |
| Abbott Laboratories | $24.93 | 2024 | Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.13 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Electromed, INC. | $14.59 | 2023 | Smartvest |
| Amgen INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aniko Toth-Bagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.